Valuation models
price $250.48 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused141.48 – 237.08177.7741% overvaluedDCF · Perpetuity growth · 10y172.47 – 277.16212.4618% overvaluedDCF · EBITDA exit · 5y269.57 – 295.72282.2811% undervaluedDCF · EBITDA exit · 10y279.82 – 331.12304.2318% undervaluedP/E · peers127.24 – 233.89209.9819% overvaluedP/E · own history278.03 – 479.77326.3723% undervaluedPEG—300.9317% undervaluedEV/EBITDA · peers115.24 – 247.93207.4921% overvaluedEV/Revenue · peers177.48 – 709.45263.215% undervaluedEarnings power value35.49 – 65.8247.47428% overvaluedDividend discount42.24 – 127.0566.14279% overvaluedWall St. consensus target—276.009% belowCost of capital (WACC)—7.14%—
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
177.77
Cardinal Health closed at $250.48 — overvalued by 41% vs model.
141.48the model's range237.08
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
47.47 – 326.37
Wall St. target
276.00 9% below
Above model, 1y
18 of 30 days
How it is valued
Valued asMature & stable
Low/slowing growth (~6% recent)Thin margins (0.7% net margin)Highly cyclical earningsHigh leverage (D/E 5.0x)Strong FCF yield (7.8%)
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.